News

Three-month time point critical in T2T


 

FROM ANNALS OF THE RHEUMATIC DISEASES

References

Three months marks a critical time point that determines whether a rheumatoid arthritis patient will reach a treatment target at 6 months, according to results of a study published in Annals of the Rheumatic Diseases.

Dr. Daniel Aletaha of the Medical University of Vienna and his associates performed a pooled analysis of clinical data from RA trials in the last decade. They found that, regardless of the starting point, 6-month success rates were clearly related to disease activity state reached at 3 months, and not so much to the number of disease activity categories improved.

©Suze777/Thinkstock.com

The results show that a response at 3 months can be used as a decision criterion in two clinical situations. Failure to achieve minor responses (for example, ACR 20, Simplified Disease Activity Index [SDAI] 50) at the 3-month mark had the potential to almost rule out successfully reaching the target at 6 months, the investigators wrote (Ann Rheum Dis. 2015. doi: 10.1136/annrheumdis-2015-208324).

Conversely, achievement of major response definitions at 3 months (for example, ACR 70, SDAI 85%) can reliably predict achievement of a good state at 6 months.

“It is also obvious therefore that for many patients in the gray zone between these response levels, the prediction may be less solid, and may – to a greater extent – rest on the physician’s decision,” they wrote.

The findings were in line with updated treat-to-target (T2T) recommendations that suggest a goal of significant improvement at 3 months and attainment of the treatment target at 6 months, they added.

The study results showed that in order to be at least 80% sensitive for achieving the low disease activity target at 6 months, a change of 58% in SDAI/Clinical Disease Activity Index needed to be observed at 3 months.

Patients who did not achieve the (minor) SDAI 50% response level had very low negative likelihood ratios of 0.28 for low disease activity and 0.07 for remission at 6 months. Patients who achieved the (major) SDAI 85% response had substantial positive likelihood ratios of 9.2 for reaching low disease activity and 6.2 for reaching remission at 6 months.

In logistic regression, the change at 3 months was significantly associated with reaching the target at 6 months.

Dr. Aletaha and one of his associates received consulting and/or speaking honoraria from AbbVie; Merck, Sharp & Dohme; Pfizer; and Roche.

Recommended Reading

Tofacitinib proves effective in RA when biologics don’t work
MDedge Rheumatology
Time a significant factor in assessing RA patients’ symptoms
MDedge Rheumatology
New IPF guidelines limit treatment choices
MDedge Rheumatology
ESC: Celecoxib safety study may soothe cardio concerns
MDedge Rheumatology
VIDEO: Use fiduciary duty to set pain medication boundaries
MDedge Rheumatology
Infliximab biosimilar SB2 shows efficacy, safety similar to Remicade for RA
MDedge Rheumatology
Biomarker test couldn’t predict RA transformation from undifferentiated arthritis
MDedge Rheumatology
Methotrexate ups risk of liver abnormalities, but not serious hepatic events
MDedge Rheumatology
MBDA score can help to predict RA radiographic progression
MDedge Rheumatology
Shoulder strength is impaired in women with early-stage RA
MDedge Rheumatology